CoChat

Identification of a brainstem locus that inhibits tumor necrosis factor

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Significance: Electronic devices that stimulate electrical activity in the vagus nerve are being studied for clinical use in rheumatoid arthritis, inflammatory bowel disease, and other inflammatory syndromes because vagus nerve signals inhibit inflammation and cytokine production. A vagus nerve mechanism, termed the inflammatory reflex, has been widely studied, but the origin and functional neuroanatomy of vagus nerve fibers controlling inflammation were previously unknown. Here we reveal cholinergic neurons in the brainstem dorsal motor nucleus (DMN) of the vagus projecting to the celiac-superior mesenteric ganglia and transmitting cytokine-inhibiting signals to the splenic nerve. By combining optogenetics, anatomical and functional mapping, and measurement of TNF production, our data show the DMN is an important brainstem locus controlling anti-inflammatory signals in the inflammatory reflex.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2008213117

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Selective activation of DMN cholinergic neurons inhibits TNF production during endotoxemia. (A–D) Confocal images showing colocalization of ChR2-eYFP and ChAT immunoreactivity in the DMN of ChAT-ChR2-eYFP mice. (A) Anti-eYFP staining, (B) DAPI, (C) anti-ChAT staining, and (D) merged image of anti-eYFP, DAPI, and anti-ChAT staining. Note the strong expression of ChR2-eYFP in cholinergic neurons in the DMN. Data are representative of two animals per group. (Scale bar, 20 μm.) 40× magnification. (E and F) Optogenetic stimulation of cholinergic neurons in the DMN attenuated serum TNF in endotoxemic mice. ChAT-ChR2-eYFP mice were subjected to sham stimulation or optogenetic stimulation using (E) blue light (473 nm, 20 Hz, 25% duty cycle, 5 min) or (F) yellow light (593.5 nm, 20 Hz, 25% duty cycle, 5 min) in the left DMN. Animals were allowed to recover for 24 h and then injected intraperitoneally with LPS. Serum was obtained 90 min post-LPS administration and TNF was measured by ELISA. Stimulation of ChR2-expressing DMN cholinergic neurons with blue light, but not with yellow light, suppressed TNF levels during endotoxemia in ChAT-ChR2-eYFP mice. Data are represented as individual mouse data points with mean ± SEM. Unpaired t test: sham versus optogenetic stimulation (***P < 0.001, n = 19 to 20 per group). (G–J) Confocal images showing the absence of ChR2-eYFP in cholinergic neurons in littermate control mice. (G) Anti-eYFP staining, (H) DAPI, (I) anti-ChAT staining, and (J) merged image of anti-eYFP, DAPI, and anti-ChAT staining. Data are representative of two animals per group. (Scale bar, 20 μm.) 40× magnification. (K) Optogenetic stimulation in the DMN using blue light (473 nm, 20Hz, 25% duty cycle, 5 min) failed to suppress TNF production in ChR2-eYFP littermate controls. Data are represented as individual mouse data points with mean ± SEM. n = 11 to 12 per group.
Fig. 1. Selective activation of DMN cholinergic neurons inhibits TNF production during endotoxemia. (A–D) Confocal images showing colocalization of ChR2-eYFP and ChAT immunoreactivity in the DMN of ChAT-ChR2-eYFP mice. (A) Anti-eYFP staining, (B) DAPI, (C) anti-ChAT staining, and (D) merged image of anti-eYFP, DAPI, and anti-ChAT staining. Note the strong expression of ChR2-eYFP in cholinergic neurons in the DMN. Data are representative of two animals per group. (Scale bar, 20 μm.) 40× magnification. (E and F) Optogenetic stimulation of cholinergic neurons in the DMN attenuated serum TNF in endotoxemic mice. ChAT-ChR2-eYFP mice were subjected to sham stimulation or optogenetic stimulation using (E) blue light (473 nm, 20 Hz, 25% duty cycle, 5 min) or (F) yellow light (593.5 nm, 20 Hz, 25% duty cycle, 5 min) in the left DMN. Animals were allowed to recover for 24 h and then injected intraperitoneally with LPS. Serum was obtained 90 min post-LPS administration and TNF was measured by ELISA. Stimulation of ChR2-expressing DMN cholinergic neurons with blue light, but not with yellow light, suppressed TNF levels during endotoxemia in ChAT-ChR2-eYFP mice. Data are represented as individual mouse data points with mean ± SEM. Unpaired t test: sham versus optogenetic stimulation (***P < 0.001, n = 19 to 20 per group). (G–J) Confocal images showing the absence of ChR2-eYFP in cholinergic neurons in littermate control mice. (G) Anti-eYFP staining, (H) DAPI, (I) anti-ChAT staining, and (J) merged image of anti-eYFP, DAPI, and anti-ChAT staining. Data are representative of two animals per group. (Scale bar, 20 μm.) 40× magnification. (K) Optogenetic stimulation in the DMN using blue light (473 nm, 20Hz, 25% duty cycle, 5 min) failed to suppress TNF production in ChR2-eYFP littermate controls. Data are represented as individual mouse data points with mean ± SEM. n = 11 to 12 per group.CC BY-NC-ND · PubMed Central
Fig. 2. The efferent vagus nerve fibers terminate in close proximity to the splenic nerve in the celiac-superior mesenteric ganglion complex. (A) Identification of the celiac-superior mesenteric ganglion complex in ChAT-eGFP transgenic mice, which allow fluorescent visualization of cholinergic structures. Using fluorescent stereomicroscopy, the celiac-superior mesenteric ganglion complex was localized on the ventral side of the descending aorta, supero-medial to the kidneys. RCG, right celiac ganglion; LCG, left celiac ganglion; SMG, superior mesenteric ganglion. Data are representative of two animals per group. (B) Only autofluorescence was seen in control C57BL/6 mice using fluorescent stereomicroscopy on the same area. (C) Schematic depiction of the viral tracing strategy, which involved infection of a Cre-dependent AAV (AAV5- ChR2-eYFP) into the DMN and a Cre-dependent HSV (HSV-ChR2-mCherry) into the spleen parenchyma of Syn-Cre mice. (D–G) eYFP-expressing efferent vagus terminals and NeuN+ nerve cell bodies were visualized by immunohistochemistry in the celiac-superior mesenteric ganglia. (D) anti-eYFP staining, (E) DAPI, (F) anti-NeuN staining, (G) merged image of anti-eYFP, anti-NeuN, and DAPI staining. Note eYFP-expressing efferent vagus terminals in close proximity to NeuN-expressing nerve cell bodies. Data are representative of two animals per group. (Scale bar, 25 μm.) 40× magnification. (H–L) Colocalization analysis of synaptophysin and eYFP in presynaptic efferent vagus nerve terminals in the celiac-superior mesenteric ganglion complex. (H) Anti-eYFP staining, (I) anti-synaptophysin staining, (J) merged image of anti-eYFP, and anti-synaptophysin staining. (K) Colocalization mask showing overlap regions of eYFP and synaptophysin labeling. (L) Mander’s coefficient values for overlap proportion. Presynaptic terminals labeled with anti-synaptophysin colocalized with anti-eYFP with a proportion of 0.25 ± 0.3 (Mander’s coefficient), indicating that vagus nerve fibers originating from the DMN terminate in the celiac-superior mesenteric ganglion complex. (Scale bar, 20 μm.) 63× magnification. (M–O) eYFP-expressing efferent vagus terminals and mCherry-expressing splenic nerve cell bodies were visualized by immunohistochemistry in the celiac-superior mesenteric ganglion complex. (M) DAPI, (N) mCherry, (O) merged image of anti-eYFP, anti-synaptophysin, mCherry and DAPI staining. (Scale bar, 20 μm.) 63× magnification. Note a substantial proportion (41.3 ± 3.4%) of synaptophysin+ eYFP+ presynaptic vagus terminals are located in close proximity (<300 nm) to splenic neurons retrogradely labeled by HSV-mCherry.
Fig. 2. The efferent vagus nerve fibers terminate in close proximity to the splenic nerve in the celiac-superior mesenteric ganglion complex. (A) Identification of the celiac-superior mesenteric ganglion complex in ChAT-eGFP transgenic mice, which allow fluorescent visualization of cholinergic structures. Using fluorescent stereomicroscopy, the celiac-superior mesenteric ganglion complex was localized on the ventral side of the descending aorta, supero-medial to the kidneys. RCG, right celiac ganglion; LCG, left celiac ganglion; SMG, superior mesenteric ganglion. Data are representative of two animals per group. (B) Only autofluorescence was seen in control C57BL/6 mice using fluorescent stereomicroscopy on the same area. (C) Schematic depiction of the viral tracing strategy, which involved infection of a Cre-dependent AAV (AAV5- ChR2-eYFP) into the DMN and a Cre-dependent HSV (HSV-ChR2-mCherry) into the spleen parenchyma of Syn-Cre mice. (D–G) eYFP-expressing efferent vagus terminals and NeuN+ nerve cell bodies were visualized by immunohistochemistry in the celiac-superior mesenteric ganglia. (D) anti-eYFP staining, (E) DAPI, (F) anti-NeuN staining, (G) merged image of anti-eYFP, anti-NeuN, and DAPI staining. Note eYFP-expressing efferent vagus terminals in close proximity to NeuN-expressing nerve cell bodies. Data are representative of two animals per group. (Scale bar, 25 μm.) 40× magnification. (H–L) Colocalization analysis of synaptophysin and eYFP in presynaptic efferent vagus nerve terminals in the celiac-superior mesenteric ganglion complex. (H) Anti-eYFP staining, (I) anti-synaptophysin staining, (J) merged image of anti-eYFP, and anti-synaptophysin staining. (K) Colocalization mask showing overlap regions of eYFP and synaptophysin labeling. (L) Mander’s coefficient values for overlap proportion. Presynaptic terminals labeled with anti-synaptophysin colocalized with anti-eYFP with a proportion of 0.25 ± 0.3 (Mander’s coefficient), indicating that vagus nerve fibers originating from the DMN terminate in the celiac-superior mesenteric ganglion complex. (Scale bar, 20 μm.) 63× magnification. (M–O) eYFP-expressing efferent vagus terminals and mCherry-expressing splenic nerve cell bodies were visualized by immunohistochemistry in the celiac-superior mesenteric ganglion complex. (M) DAPI, (N) mCherry, (O) merged image of anti-eYFP, anti-synaptophysin, mCherry and DAPI staining. (Scale bar, 20 μm.) 63× magnification. Note a substantial proportion (41.3 ± 3.4%) of synaptophysin+ eYFP+ presynaptic vagus terminals are located in close proximity (<300 nm) to splenic neurons retrogradely labeled by HSV-mCherry.CC BY-NC-ND · PubMed Central
Fig. 3. Optogenetic stimulation of cholinergic neurons in the DMN induces evoked action potentials in the splenic nerve. (A and B) Splenic nerve activity in response to blue light stimulation (light on) of the DMN cholinergic neurons (473 nm, 25% duty cycle, 8 to 12 mW total power, 2 to 3 min duration). Blue boxes indicate periods of light stimulation. Representative recordings shown for (A) non-ChR2 littermate control (B) ChAT-ChR2-eYFP mice. Data are representative of 7 to 10 animals per group. (C and D) Optogenetic stimulation of DMN cholinergic neurons produced a significant increase in splenic nerve activity in ChAT-ChR2-eYFP mice. Firing frequency was recorded in the splenic nerve over a 2-min stimulation period in (C) non-ChR2 littermate control, (n = 7), (D) ChAT-ChR2-eYFP mice (n = 10). Data are represented as individual mouse data points with mean ± SEM. Two-tailed t test: baseline versus optogenetic stimulation (**P < 0.01). (E and F) Optogenetic stimulation of DMN cholinergic neurons following bupivacaine administration to the left cervical vagus nerve failed to induce evoked potentials in the splenic nerve. (E) Splenic nerve activity was recorded during optogenetic stimulation (473 nm, 25% duty cycle, 8 to 12 mW total power, 2 min duration) of the DMN pre- and postbupivacaine administration. Blue boxes indicate periods of light stimulation. Representative neural recording shown. Data are representative of five animals. (F) Total spike count measured in splenic nerve following optogenetic stimulation of the DMN. Data are represented as individual mouse data points with mean ± SEM. Two-tailed t test: sham versus DMN stimulation (***P < 0.001, n = 11), vehicle versus bupivacaine administration (**P < 0.01, n = 5). No significant difference in the baseline splenic nerve activity was observed after the addition of bupivacaine to the left cervical vagus nerve.
Fig. 3. Optogenetic stimulation of cholinergic neurons in the DMN induces evoked action potentials in the splenic nerve. (A and B) Splenic nerve activity in response to blue light stimulation (light on) of the DMN cholinergic neurons (473 nm, 25% duty cycle, 8 to 12 mW total power, 2 to 3 min duration). Blue boxes indicate periods of light stimulation. Representative recordings shown for (A) non-ChR2 littermate control (B) ChAT-ChR2-eYFP mice. Data are representative of 7 to 10 animals per group. (C and D) Optogenetic stimulation of DMN cholinergic neurons produced a significant increase in splenic nerve activity in ChAT-ChR2-eYFP mice. Firing frequency was recorded in the splenic nerve over a 2-min stimulation period in (C) non-ChR2 littermate control, (n = 7), (D) ChAT-ChR2-eYFP mice (n = 10). Data are represented as individual mouse data points with mean ± SEM. Two-tailed t test: baseline versus optogenetic stimulation (**P < 0.01). (E and F) Optogenetic stimulation of DMN cholinergic neurons following bupivacaine administration to the left cervical vagus nerve failed to induce evoked potentials in the splenic nerve. (E) Splenic nerve activity was recorded during optogenetic stimulation (473 nm, 25% duty cycle, 8 to 12 mW total power, 2 min duration) of the DMN pre- and postbupivacaine administration. Blue boxes indicate periods of light stimulation. Representative neural recording shown. Data are representative of five animals. (F) Total spike count measured in splenic nerve following optogenetic stimulation of the DMN. Data are represented as individual mouse data points with mean ± SEM. Two-tailed t test: sham versus DMN stimulation (***P < 0.001, n = 11), vehicle versus bupivacaine administration (**P < 0.01, n = 5). No significant difference in the baseline splenic nerve activity was observed after the addition of bupivacaine to the left cervical vagus nerve.CC BY-NC-ND · PubMed Central
Fig. 4. Efferent cholinergic signals transmitted in the vagus nerve induce evoked action potentials in the splenic nerve. (A–C) Evoked splenic nerve compound action potentials increase in response to increasing intensities of electrical cervical vagus nerve stimulation. (A) Schematic depiction of the recording strategy. (B–C) Stimulation (0.25 ms biphasic pulses of 0, 0.1, 0.5, 1 mA) was delivered to the cervical vagus nerve, and evoked compound action potentials were recorded on the splenic nerve and subdiaphragmatic vagus nerve. Representative traces of (B) splenic nerve, (C) subdiaphragmatic vagus nerve. Data is representative of 3 animals per group. (D–G) Efferent signals transmitted in the cervical vagus nerve induce evoked action potentials in the splenic nerve. (D) Schematic depiction of the vagotomy and recording strategy. After caudal or rostral vagotomy (with respect to stimulating electrode), vagus nerve stimulation-induced evoked potentials were recorded. Representative traces of (E) splenic nerve, (F) subdiaphragmatic vagus nerve. Data is representative of 7 animals per group. (G) Caudal but not rostral vagotomy abrogates evoked action potentials in the splenic nerve. Data is represented as individual rat data point with mean ± SEM. One-way paired mixed-effects model followed by Tukey’s multiple comparisons test between groups: intact versus caudal vagotomy (P < 0.0001, n = 7), rostral versus caudal vagotomy (P = 0.0008, n = 7). (H–J) Splenic nerve activity in response to vagus nerve stimulation recorded after splenic neurectomy (proximal or distal to the splenic nerve recording electrode), (H) Schematic depiction of the splenic neurectomy and recording strategy. After proximal or distal splenic neurectomy (with respect to recording electrode) vagus nerve stimulation-induced evoked potentials were recorded, (I) Representative traces of compound action potentials in the splenic nerve. Data is representative of 3 animals per group, (J) Splenic neurectomy that was proximal but not distal to the splenic nerve recording electrode abrogates evoked action potentials in the splenic nerve. Data is represented as individual rat data point with mean ± SEM. Paired mixed-effects model followed by Tukey’s multiple comparisons test between groups: intact versus proximal splenic neurectomy (P = 0.02, n = 3). (K–M) Blocking of cholinergic signaling with hexamethonium bromide (10 mg/kg) abrogates cervical vagus nerve-originating evoked potentials in the splenic nerve. Vagus nerve stimulation-induced evoked potentials were recorded in the (K) splenic nerve and (L) sub-diaphragmatic vagus nerve before injection and at 20 min post-injection. Representative examples of evoked potentials (n = 4 per group). (M) Area under the curve (AUC) of the splenic nerve activity. Data is represented as individual rat data point with mean ± SEM. Paired t-test between two groups: Pre-treatment versus post-treatment with hexamethonium bromide (P = 0.0005, n = 4). (N) Splenic nerve stimulation attenuates LPS-induced serum TNF response. Data is represented as individual rat data point with mean ± SEM. One-way ANOVA followed by Dunnett’s multiple comparisons test between groups: sham versus VNS (P < 0.001), sham versus SNS (P < 0.01).
Fig. 4. Efferent cholinergic signals transmitted in the vagus nerve induce evoked action potentials in the splenic nerve. (A–C) Evoked splenic nerve compound action potentials increase in response to increasing intensities of electrical cervical vagus nerve stimulation. (A) Schematic depiction of the recording strategy. (B–C) Stimulation (0.25 ms biphasic pulses of 0, 0.1, 0.5, 1 mA) was delivered to the cervical vagus nerve, and evoked compound action potentials were recorded on the splenic nerve and subdiaphragmatic vagus nerve. Representative traces of (B) splenic nerve, (C) subdiaphragmatic vagus nerve. Data is representative of 3 animals per group. (D–G) Efferent signals transmitted in the cervical vagus nerve induce evoked action potentials in the splenic nerve. (D) Schematic depiction of the vagotomy and recording strategy. After caudal or rostral vagotomy (with respect to stimulating electrode), vagus nerve stimulation-induced evoked potentials were recorded. Representative traces of (E) splenic nerve, (F) subdiaphragmatic vagus nerve. Data is representative of 7 animals per group. (G) Caudal but not rostral vagotomy abrogates evoked action potentials in the splenic nerve. Data is represented as individual rat data point with mean ± SEM. One-way paired mixed-effects model followed by Tukey’s multiple comparisons test between groups: intact versus caudal vagotomy (P < 0.0001, n = 7), rostral versus caudal vagotomy (P = 0.0008, n = 7). (H–J) Splenic nerve activity in response to vagus nerve stimulation recorded after splenic neurectomy (proximal or distal to the splenic nerve recording electrode), (H) Schematic depiction of the splenic neurectomy and recording strategy. After proximal or distal splenic neurectomy (with respect to recording electrode) vagus nerve stimulation-induced evoked potentials were recorded, (I) Representative traces of compound action potentials in the splenic nerve. Data is representative of 3 animals per group, (J) Splenic neurectomy that was proximal but not distal to the splenic nerve recording electrode abrogates evoked action potentials in the splenic nerve. Data is represented as individual rat data point with mean ± SEM. Paired mixed-effects model followed by Tukey’s multiple comparisons test between groups: intact versus proximal splenic neurectomy (P = 0.02, n = 3). (K–M) Blocking of cholinergic signaling with hexamethonium bromide (10 mg/kg) abrogates cervical vagus nerve-originating evoked potentials in the splenic nerve. Vagus nerve stimulation-induced evoked potentials were recorded in the (K) splenic nerve and (L) sub-diaphragmatic vagus nerve before injection and at 20 min post-injection. Representative examples of evoked potentials (n = 4 per group). (M) Area under the curve (AUC) of the splenic nerve activity. Data is represented as individual rat data point with mean ± SEM. Paired t-test between two groups: Pre-treatment versus post-treatment with hexamethonium bromide (P = 0.0005, n = 4). (N) Splenic nerve stimulation attenuates LPS-induced serum TNF response. Data is represented as individual rat data point with mean ± SEM. One-way ANOVA followed by Dunnett’s multiple comparisons test between groups: sham versus VNS (P < 0.001), sham versus SNS (P < 0.01).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. B. Stilling, Ueber die Textur der Medulla oblongata (Erlangen F Enke, 1843).

Cited by

See all 133

Metadata

Authors
Kressel, A. M., Tsaava, T., Levine, Y. A., Chang, E. H., Addorisio, M. E., Chang, Q., Burbach, B. J., Carnevale, D., Lembo, G., Zador, A. M., Andersson, U., Pavlov, V. A., Chavan, S. S., & Tracey, K. J.
Affiliations
  • Northwell Health (US)
  • Institute of Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030;
  • Setpoint Medical, Valencia, CA 91355;
  • Cold Spring Harbor Laboratory (US)
  • Istituto Neurologico Mediterraneo (IT)
  • Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital, 17176 Stockholm, Sweden;
Corresponding author
  • Pavlov, Valentin A.
  • Chavan, Sangeeta S.
  • Tracey, Kevin J.
Venue
Proceedings of the National Academy of Sciences
Published
2020-11-09
Volume
117
Issue
47
Pages
29803-29810
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3098150983
Cited by
133
References
51
Citations by year
2026: 22 · 2025: 22 · 2024: 19 · 2023: 20 · 2022: 23 · 2021: 26 · 2020: 1
FWCI
6.78
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
Funders
  • NIH/NIGMS (1R01GM132672-01, 1R35GM118182-01, 1R01GM128008-01)
  • NIH/NIAID (1P01AI102852-01A1)
Topics
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
TNF-α, vagus nerve, cholinergic neurons, splenic nerve, neuroimmune regulation, cytokine inhibition, vagal reflex, optogenetics
MeSH terms
Action Potentials, Animals, Disease Models, Animal, Ganglia, Sympathetic, Humans, Inflammation, Lipopolysaccharides, Male, Medulla Oblongata, Mice, Transgenic, Spleen, Stereotaxic Techniques, Vagus Nerve, Signal Transduction, Endotoxemia, Tumor Necrosis Factors, Mice, Rats, Cholinergic Neurons, Optogenetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of a brainstem locus that inhibits tumor necrosis factor. https://app.cochat.ai/papers/10.1073/pnas.2008213117
The paper
Kressel, A. M., Tsaava, T., Levine, Y. A., Chang, E. H., Addorisio, M. E., Chang, Q., Burbach, B. J., Carnevale, D., Lembo, G., Zador, A. M., Andersson, U., Pavlov, V. A., Chavan, S. S., & Tracey, K. J. (2020). Identification of a brainstem locus that inhibits tumor necrosis factor. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2008213117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.